Frequently Asked Questions
The market is segmented based on , By Product (Consumables and Kits), Circulating Biomarkers (Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), ctRNA, Circulating Tumor Cells (CTCs), cfRNA, and Others), End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, and Pathology Laboratories) - Industry Trends and Forecast to 2030.
.
The Global Breast Cancer Liquid Biopsy Market size was valued at USD 278.07 USD Million in 2022.
The Global Breast Cancer Liquid Biopsy Market is projected to grow at a CAGR of 23.09% during the forecast period of 2023 to 2030.
The major players operating in the market include , F. Hoffmann,La Roche , Thermo Fisher Scientific , Abbott , Agilent Technologies , Merck KGaA , QIAGEN , Abcam plc. , Cell Signaling Technology , Koninklijke Philips N.V. , The Menarini Group , Genomic Health , Johnson & Johnson Private Limited. , Medtronic , Siemens Healthineers , Biocept , Bio,Rad Laboratories , Fluxion Biosciences , FOUNDATION MEDICINE , Sysmex Inostics , ExoDx , Illumina ,.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
